Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.

Soeria-Atmadja S, Österberg E, Gustafsson LL, Dahl ML, Eriksen J, Rubin J, Navér L.

PLoS One. 2017 Sep 8;12(9):e0181316. doi: 10.1371/journal.pone.0181316. eCollection 2017.

2.

Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.

Janssen EJH, Bastiaans DET, Välitalo PAJ, van Rossum AMC, Jacqz-Aigrain E, Lyall H, Knibbe CAJ, Burger DM.

Br J Clin Pharmacol. 2017 Jun;83(6):1287-1297. doi: 10.1111/bcp.13227. Epub 2017 Feb 14.

PMID:
28079918
3.

Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen.

Moholisa RR, Schomaker M, Kuhn L, Meredith S, Wiesner L, Coovadia A, Strehlau R, Martens L, Abrams EJ, Maartens G, McIlleron H.

Antivir Ther. 2014;19(4):399-406. doi: 10.3851/IMP2749. Epub 2014 Feb 12.

4.

24-Month adherence, tolerance and efficacy of once-a-day antiretroviral therapy with didanosine, lamivudine, and efavirenz in African HIV-1 infected children: ANRS 12103/12167.

Hien H, Meda N, Diagbouga S, Zoure E, Yaméogo S, Tamboura H, Somé J, Ouiminga A, Rouet F, Drabo A, Hien A, Nicolas J, Chappuy H, Van de Perre P, Msellati P, Nacro B.

Afr Health Sci. 2013 Jun;13(2):287-94. doi: 10.4314/ahs.v13i2.13.

5.

Incidence and risk factors for first line anti retroviral treatment failure among Ugandan children attending an urban HIV clinic.

Sebunya R, Musiime V, Kitaka SB, Ndeezi G.

AIDS Res Ther. 2013 Nov 11;10(1):25. doi: 10.1186/1742-6405-10-25.

6.

Rate of candidiasis among HIV-infected children in Spain in the era of highly active antiretroviral therapy (1997-2008).

Álvaro-Meca A, Jensen J, Micheloud D, Díaz A, Gurbindo D, Resino S.

BMC Infect Dis. 2013 Mar 4;13:115. doi: 10.1186/1471-2334-13-115.

7.

Paediatric HIV--trends & challenges.

Mothi SN, Karpagam S, Swamy VH, Mamatha ML, Sarvode SM.

Indian J Med Res. 2011 Dec;134(6):912-9. doi: 10.4103/0971-5916.92636. Review.

8.

Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children.

Martinez BL, Riordan FA.

HIV AIDS (Auckl). 2010;2:59-67. Epub 2010 Mar 29.

9.

Risk of triple-class virological failure in children with HIV: a retrospective cohort study.

Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, van Sighem A, Ramos JT, Warsawski J, Thorne C, Noguera-Julian A, Obel N, Costagliola D, Tookey PA, Colin C, Kjaer J, Grarup J, Chene G, Phillips A.

Lancet. 2011 May 7;377(9777):1580-7. doi: 10.1016/S0140-6736(11)60208-0. Epub 2011 Apr 20.

10.

Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.

Pollock L, Else L, Poerksen G, Molyneux E, Moons P, Walker S, Fraser W, Back D, Khoo S.

J Antimicrob Chemother. 2009 Dec;64(6):1251-9. doi: 10.1093/jac/dkp358. Epub 2009 Oct 6.

11.

Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children.

Pensieroso S, Cagigi A, Palma P, Nilsson A, Capponi C, Freda E, Bernardi S, Thorstensson R, Chiodi F, Rossi P.

Proc Natl Acad Sci U S A. 2009 May 12;106(19):7939-44. doi: 10.1073/pnas.0901702106. Epub 2009 Apr 27.

12.

Management of paediatric HIV-1 resistance.

Gupta RK, Gibb DM, Pillay D.

Curr Opin Infect Dis. 2009 Jun;22(3):256-63. Review.

13.

Early antiretroviral therapy and mortality among HIV-infected infants.

Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, Jean-Philippe P, McIntyre JA; CHER Study Team.

N Engl J Med. 2008 Nov 20;359(21):2233-44. doi: 10.1056/NEJMoa0800971.

14.

A feasibility study of immediate versus deferred antiretroviral therapy in children with HIV infection.

Ananworanich J, Kosalaraksa P, Siangphoe U, Engchanil C, Pancharoen C, Lumbiganon P, Intasan J, Apateerapong W, Chuenyam T, Ubolyam S, Bunupuradah T, Lange J, Cooper DA, Phanuphak P; HIV-NAT 010 Study Team.

AIDS Res Ther. 2008 Oct 28;5:24. doi: 10.1186/1742-6405-5-24.

15.

Type I interferon-dependent gene MxA in perinatal HIV-infected patients under antiretroviral therapy as marker for therapy failure and blood plasmacytoid dendritic cells depletion.

Badolato R, Ghidini C, Facchetti F, Serana F, Sottini A, Chiarini M, Spinelli E, Lonardi S, Plebani A, Caimi L, Imberti L.

J Transl Med. 2008 Sep 9;6:49. doi: 10.1186/1479-5876-6-49.

16.

When should children with HIV infection be started on antiretroviral therapy?

Welch SB, Gibb D.

PLoS Med. 2008 Mar 25;5(3):e73. doi: 10.1371/journal.pmed.0050073.

17.

Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study.

Menson EN, Walker AS, Sharland M, Wells C, Tudor-Williams G, Riordan FA, Lyall EG, Gibb DM; Collaborative HIV Paediatric Study Steering Committee.

BMJ. 2006 May 20;332(7551):1183-7.

Supplemental Content

Support Center